The U.S. House of Representatives has passed legislation that could effectively end most academic research collaborations between the United States and China, reflecting ongoing geopolitical tensions. Known as the SAFE Act, the provision is included within a defense spending bill but may be subject to revision or repeal. Separately, ongoing legal disputes and federal scrutiny over drug pricing programs, including 340B, continue to influence pharmaceutical industry dynamics and policy considerations. These regulatory shifts signify increasing governmental influence over international research engagement and healthcare pricing frameworks.